TY - JOUR T1 - A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine JF - bioRxiv DO - 10.1101/2020.07.30.229120 SP - 2020.07.30.229120 AU - Weina Sun AU - Stephen McCroskery AU - Wen-Chun Liu AU - Sarah R. Leist AU - Yonghong Liu AU - Randy A. Albrecht AU - Stefan Slamanig AU - Justine Oliva AU - Fatima Amanat AU - Alexandra Schäfer AU - Kenneth H. Dinnon III AU - Bruce L. Innis AU - Adolfo García-Sastre AU - Florian Krammer AU - Ralph S. Baric AU - Peter Palese Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/07/31/2020.07.30.229120.abstract N2 - A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.Competing Interest StatementThe authors have declared no competing interest. ER -